WO2020078402A1 - 作为TGF-βR1抑制剂的化合物及其应用 - Google Patents
作为TGF-βR1抑制剂的化合物及其应用 Download PDFInfo
- Publication number
- WO2020078402A1 WO2020078402A1 PCT/CN2019/111568 CN2019111568W WO2020078402A1 WO 2020078402 A1 WO2020078402 A1 WO 2020078402A1 CN 2019111568 W CN2019111568 W CN 2019111568W WO 2020078402 A1 WO2020078402 A1 WO 2020078402A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- alkoxy
- amino
- alkylamino
- hydroxy
- Prior art date
Links
- 0 CC(C)*(C=C([C@]1C(*)=CC(*)=C*(C)C1)Oc1c(*)[n](*)nc1*)C=I Chemical compound CC(C)*(C=C([C@]1C(*)=CC(*)=C*(C)C1)Oc1c(*)[n](*)nc1*)C=I 0.000 description 3
- YYLCWMCHEMQVMM-UHFFFAOYSA-N COc(c(C(N)=O)c1)cc2c1c(Oc1c[n](C3CC3)nc1C1CCOCC1)ccn2 Chemical compound COc(c(C(N)=O)c1)cc2c1c(Oc1c[n](C3CC3)nc1C1CCOCC1)ccn2 YYLCWMCHEMQVMM-UHFFFAOYSA-N 0.000 description 1
- FLSBPAVHCYFIBS-UHFFFAOYSA-N CS(N(CC1)CC=C1c1cc2nccc(Oc3c[n](C4CC4)nc3C3CCOCC3)c2cc1)(=O)=O Chemical compound CS(N(CC1)CC=C1c1cc2nccc(Oc3c[n](C4CC4)nc3C3CCOCC3)c2cc1)(=O)=O FLSBPAVHCYFIBS-UHFFFAOYSA-N 0.000 description 1
- WFQXKRSDLRRRGM-UHFFFAOYSA-N C[n]1ncc(-c(cc2)cc3c2c(Oc2c[n](C4CC4)nc2-c2ccccc2)ccn3)c1 Chemical compound C[n]1ncc(-c(cc2)cc3c2c(Oc2c[n](C4CC4)nc2-c2ccccc2)ccn3)c1 WFQXKRSDLRRRGM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the present invention belongs to the field of medicinal chemistry, and specifically relates to a class of TGF- ⁇ R1 inhibitor compounds or pharmaceutically acceptable salts, isomers, solvates, crystals or prodrugs thereof, methods for their preparation, and pharmaceutical combinations containing these compounds And the use of these compounds or compositions for the treatment and / or prevention of diseases related to TGF- ⁇ R1 expression, such as the treatment of diseases such as cancer and myelodysplastic syndrome.
- TGF- ⁇ transforming growth factor ⁇
- TGF- ⁇ 1 ⁇ 6 6 different subtypes (TGF- ⁇ 1 ⁇ 6) have been found, and their homology is different from each other. Only three subtypes are expressed, namely TGF- ⁇ 1, TGF- ⁇ 2 and TGF- ⁇ 3. It is a multi-functional growth factor superfamily with a wide range of biological activities, involved in early embryonic development, cartilage and bone formation, synthesis of extracellular matrix, inflammation, interstitial fibrosis, regulation of immune and endocrine functions, tumor Formation and development.
- TGF- ⁇ 1 is the most common and important subtype of TGF ⁇ . It is the most abundantly expressed subtype in the liver and the strongest known liver fibrosis inducing factor. It develops from chronic liver disease to end-stage liver disease. Plays an important role (Yamazaki, et al. Digestive Disease, 2011, 29: 284-288). Multiple studies have shown that TGF- ⁇ 1 and TGF ⁇ receptors are usually highly expressed in liver disease organs, blood vessels and extracellular matrix.
- TGF- ⁇ 1 activates TGF ⁇ R1 (transforming growth factor ⁇ receptor 1, ALK5) in the signaling pathway, thereby regulating the entire signaling pathway, and regulating a series of related to fibrosis and tumorigenesis Target gene expression.
- TGF- ⁇ has a promotion effect on liver cancer mainly in promoting tumor cell metastasis, strengthening tumor cell immune escape and inducing angiogenesis (Ling, et al. Current Pharmaceutical Biotechnology, 2011, 12: 2190-2202) .
- TGF ⁇ R1 inhibitors such as Galunisertib and others have shown certain cardiotoxicity (such as bleeding, functional degradation, inflammatory injury, etc.) in animal models.
- the reason is Due to the low target selectivity and specificity of these drugs, while inhibiting the TGF ⁇ R1 kinase activation site, the drugs also have a strong inhibitory effect on other proteins with the same kinase region (such as p38 ⁇ ), which in turn produces many Expected off-target side effects. Therefore, there is still a need to develop more selective inhibitors of TGF ⁇ R1 in order to specifically regulate the TGF- ⁇ signaling pathway for the treatment of TGF- ⁇ -related diseases.
- An object of the present invention is to provide a compound represented by the following general formula I having TGF- ⁇ R1 inhibitory activity or a pharmaceutically acceptable salt, isomer, solvate, crystal or prodrug thereof,
- Another object of the present invention is to provide a method for preparing the compound of the general formula I of the present invention or its isomer, pharmaceutically acceptable salt, solvate, crystal, electron isostere or prodrug.
- Another object of the present invention is to provide a combination of a compound of the general formula I of the present invention or its isomers, pharmaceutically acceptable salts, solvates, crystals, isosteres or prodrugs and a pharmaceutically acceptable carrier Compounds, and compositions comprising compounds of the general formula I or isomers, pharmaceutically acceptable salts, solvates, crystals, electron isosteres or prodrugs of the invention and another drug or drugs.
- Another object of the present invention is to provide compounds of the general formula I of the present invention or isomers, pharmaceutically acceptable salts, solvates, crystals, isosteres or prodrugs thereof for the treatment and / or prevention of TGF- ⁇ R1 related
- the method of the disease, and the compounds of the general formula I or isomers, pharmaceutically acceptable salts, solvates, crystals, electron isosteres or prodrugs of the present invention are prepared for the treatment and / or prevention of TGF- Application of drugs in diseases related to ⁇ R1.
- the present invention provides compounds or prodrugs of the compound represented by general formula I or its isomers, pharmaceutically acceptable salts, solvates, crystals, electrons, etc.,
- X 1 is selected from N and CH;
- R 1 is selected from the group consisting of hydroxy, cyano, carboxy, nitro, alkyl, haloalkyl, hydroxyalkyl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, cycloalkylalkoxy, heterocycle Alkoxy, cycloalkylalkyl, heterocyclylalkyl, monoalkylamino, dialkylamino, cycloalkylamino, heterocyclylamino, arylamino, heteroarylamino, cycloalkyl, Heterocyclyl, aryl, heteroaryl, arylheterocyclyl, and heteroarylheterocyclyl, which are optionally substituted by one or more halogen, hydroxy, amino, carboxy, cyano, nitro, oxo Group, alkylsulfonyl, aminosulfonyl, alkylsulfonylalkyl, alkyl, cycloalkyl
- R 2 and R 3 are independently selected from hydrogen, halogen, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, hydroxyalkoxy, nitro, carboxy, cyano, amino, mono Alkylamino, alkylacylamino, alkylacyl, aminoacyl, alkylaminoacyl, dialkylamino, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl, wherein Halogen, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, hydroxyalkoxy, nitro, carboxyl, cyano, amino, monoalkylamino, alkylacylamino, alkylacyl , Aminoacyl, alkylaminoacyl, dialkylamino, alkenyl, alkynyl, cycloalkyl, heterocyclyl,
- R 4 is selected from hydrogen, halogen, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, hydroxyalkoxy, nitro, carboxy, cyano, amino, alkylamino, alkylacyl Amino, alkylacyl, aminoacyl, alkylaminoacyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylamino, heterocycloalkylaryl, arylamino and heteroarylamino , Wherein the halogen, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, hydroxyalkoxy, nitro, carboxy, cyano, amino, alkylamino, alkylacylamino, Alkyl acyl, aminoacyl, alkylaminoacyl, cycloalkyl, heterocycloalkyl, aryl, heteroary
- R 5 and R 6 are independently selected from hydrogen, halogen, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, hydroxyalkoxy, nitro, carboxy, cyano, amino, mono Alkylamino, alkylacylamino, alkylacyl, aminoacyl, alkylaminoacyl, dialkylamino and cycloalkyl;
- n and n are independently selected from 1, 2, and 3, respectively.
- the compound of the present invention is a compound of general formula I or its isomer, pharmaceutically acceptable salt, solvate, crystal, electron isostere or prodrug, wherein X 1 is N .
- the compound of the present invention is a compound of general formula I or its isomer, pharmaceutically acceptable salt, solvate, crystal, electron isostere or prodrug, wherein X 1 is CH.
- the compound of the present invention is a compound of general formula I or its isomer, pharmaceutically acceptable salt, solvate, crystal, electron isostere or prodrug, wherein: R 1 is selected from Hydroxy, cyano, carboxy, nitro, C 1-6 alkyl, halogenated C 1-6 alkyl, hydroxy C 1-6 alkyl, C 1-6 alkoxy, C 3-6 cycloalkyloxy Group, C 3-6 heterocycloalkyloxy, C 3-6 cycloalkyl C 1-3 alkoxy, C 3-6 heterocyclyl C 1-3 alkoxy, C 3-6 cycloalkyl C 1-3 alkyl, C 3-6 heterocyclyl C 1-3 alkyl, mono C 1-6 alkylamino, bis C 1-6 alkylamino, C 3-6 cycloalkylamino, C 3 -6 heterocyclylamino, C 6-12 arylamino, C 5-8 heteroarylamino, C 3-6 cycloalkyl
- R 1 is selected from hydroxyl, cyano, carboxy, nitro, C 1-6 alkyl, halogenated C 1-6 alkyl, hydroxy C 1-6 alkyl, C 1-6 alkoxy, C 3-6 cycloalkyloxy, C 3-6 heterocycloalkyloxy, C 3-6 cycloalkyl C 1-3 alkoxy, C 3-6 heterocyclyl C 1-3 alkoxy, C 3-6 cycloalkyl C 1-3 alkyl, C 3-6 heterocyclyl C 1-3 alkyl, mono C 1-6 alkylamino, di C 1-6 alkylamino, C 3-6 Cycloalkylamino, C 6-12 arylamino, C 5-8 heteroarylamino, C 3-6 heterocyclylamino, C 3-6 cycloalkyl, C 3-6 heterocyclyl, C 6- 12 aryl, C 5-12 heteroaryl, C 6-12 aryl C 3-10 heterocyclyl and C 5-12 heteroaryl C 3-6 heterocyclyl,
- R 1 is selected from hydroxyl, cyano, carboxyl, nitro, methyl, ethyl, propyl, isopropyl, trifluoromethyl, trifluoroethyl, hydroxymethyl, hydroxyethyl, hydroxy Propyl, 2-hydroxypropyl, methoxy, ethoxy, propoxy, isopropoxy, nitro, carboxy, cyano, amino, methylamino, ethylamino, propylamino, isopropyl Amino, dimethylamino, diethylamino, methylethylamino, dipropylamino, methylpropylamino, ethylpropylamino, methylacylamino, ethylacylamino, vinylacylamino, methylacyl , Ethylacyl, vinylacyl, aminoacyl, methylaminoacyl, ethylaminoacyl, vinyl, propenyl,
- the compound of the present invention is a compound of general formula I or its isomer, pharmaceutically acceptable salt, solvate, crystal, electron isostere or prodrug, wherein:
- R 2 and R 3 are independently selected from hydrogen, fluorine, chlorine, bromine, iodine, hydroxyl, C 1-6 alkyl, halogenated C 1-6 alkyl, hydroxy C 1-6 alkyl, C 1-6 Alkoxy, halogenated C 1-6 alkoxy, hydroxy C 1-6 alkoxy, nitro, carboxy, cyano, amino, mono C 1-6 alkylamino, C 1-6 alkylacylamino , C 1-6 alkylacyl, aminoacyl, C 1-6 alkylaminoacyl, bis C 1-6 alkylamino, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkane Group, 3-10 membered heterocycloalkyl group, C 6-18 aryl group and 5-18 membered heteroaryl group, wherein the fluorine, chlorine, bromine, iodine, hydroxyl, C 1-6 alkyl, halo C 1-6 alkyl, hydroxy C
- the compound of the present invention is a compound of general formula I or its isomer, pharmaceutically acceptable salt, solvate, crystal, electron isostere or prodrug, wherein:
- R 4 , R 5 and R 6 are independently selected from hydrogen, halogen, hydroxy, C 1-6 alkyl, halogenated C 1-6 alkyl, hydroxy C 1-6 alkyl, C 1-6 alkoxy , Halogenated C 1-6 alkoxy, hydroxy C 1-6 alkoxy, nitro, carboxy, cyano, amino, mono C 1-6 alkylamino, C 1-6 alkylacylamino, C 1 -6 alkylacyl, aminoacyl, C 1-6 alkylaminoacyl, bis C 1-6 alkylamino, C 3-10 cycloalkyl.
- R 4 is selected from hydrogen, halogen, hydroxy, C 1-6 alkyl, halo C 1-6 alkyl, hydroxy C 1-6 alkyl, C 1-6 alkoxy, halo C 1- 6 alkoxy, hydroxy C 1-6 alkoxy, nitro, carboxy, cyano, amino, C 1-6 alkylamino, C 1-6 alkylacylamino, C 1-6 alkylacyl, amino Acyl, C 1-6 alkylamino acyl, C 3-8 cycloalkyl, C 3-8 heterocycloalkyl, C 6-12 aryl, C 5-12 heteroaryl, C 3-8 cycloalkyl Amino, C 3-8 heterocycloalkylaryl, C 6-12 arylamino and C 5-8 heteroarylamino, wherein the halogen, hydroxy, C 1-6 alkyl, halo C 1-6 Alkyl, hydroxy C 1-6 alkyl, C 1-6 alkoxy, halogenated C 1-6 al
- the compound of general formula I of the present invention is the following compound of general formula Ia or its isomer, pharmaceutically acceptable salt, solvate, crystal, electron isostere or prodrug,
- R 2 , R 3 , R 4 , R 5 , R 6 , m, n are as defined in claims 1 to 5;
- X 2 and X 2 ′ are independently selected from N and C (R 7 ), wherein R 7 is selected from hydrogen, halogen, hydroxyl, oxo group, alkylsulfonyl, alkylsulfonylalkyl, alkyl, Haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, hydroxyalkoxy, nitro, carboxy, cyano, amino, monoalkylamino, alkylacylamino, alkylacyl, aminoacyl, alkylamino Acyl, dialkylamino and cycloalkyl;
- R 8 is selected from hydrogen, halogen, hydroxyl, oxo group, alkylsulfonyl, alkylsulfonylalkyl, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, hydroxyalkoxy, Nitro, carboxy, cyano, amino, monoalkylamino, alkylacylamino, alkylacyl, aminoacyl, alkylaminoacyl, dialkylamino, and cycloalkyl; and
- p is selected from 1, 2, and 3.
- the compound of general formula Ia or its isomer, pharmaceutically acceptable salt, solvate, crystal, electron isostere or prodrug according to the present invention wherein X 2 and X 2 ' Independently selected from N and C (R 7 ), preferably, X 2 is N and X 2 ′ is C (R 7 ) or X 2 is C (R 7 ) and X 2 ′ is N, wherein R 7 is selected From hydrogen, halogen, hydroxyl, oxo group, C 1-6 alkylsulfonyl, C 1-6 alkylsulfonyl C 1-6 alkyl, C 1-6 alkyl, halogenated C 1-6 alkyl Group, hydroxy C 1-6 alkyl, C 1-6 alkoxy, halogenated C 1-6 alkoxy, hydroxy C 1-6 alkoxy, nitro, carboxy, cyano, amino, mono C 1 -6 alkylamino, C 1-6 alkylacylamino, C
- the compound of general formula I of the present invention is the following compound of general formula Ib or its isomer, pharmaceutically acceptable salt, solvate, crystal, electron isostere or prodrug,
- R 2 , R 3 , R 4 , R 5 , R 6 , X 1 , m, n are as defined in the general formula I;
- X 3 and X 4 are independently selected from N, C, CH, CH 2 , O and S;
- Y 1 is selected from NH, C (O) NH or absent;
- R 9 is selected from hydrogen, halogen, hydroxy, oxo group, alkylsulfonyl, alkylsulfonylalkyl, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, hydroxyalkoxy, Nitro, carboxy, cyano, amino, monoalkylamino, alkylacylamino, alkylacyl, aminoacyl, alkylaminoacyl, dialkylamino, cycloalkyl; preferably, R 9 is selected from hydrogen, Fluorine, chlorine, bromine, iodine, hydroxy, methyl, ethyl, propyl, isopropyl, trifluoromethyl, trifluoroethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, 2-hydroxypropyl , Methoxy, ethoxy, propoxy, isopropoxy, nitro, carboxy, cyano, amino, methylamino
- q is selected from 1, 2, 3, 4, and 5.
- the compound of general formula I of the present invention is a compound of general formula Ic or its isomer, pharmaceutically acceptable salt, solvate, crystal, electron isostere or prodrug,
- R 2 , R 3 , R 4 , R 5 , R 6 , X 1 , m, n are as defined in the general formula I;
- Y 2 is selected from NH, C (O) NH or absent;
- R 10 is selected from hydrogen, halogen, hydroxy, oxo group, alkylsulfonyl, alkylsulfonylalkyl, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, hydroxyalkoxy, Nitro, carboxy, cyano, amino, monoalkylamino, alkylacylamino, alkylacyl, aminoacyl, alkylaminoacyl, dialkylamino, cycloalkyl; preferably, R 10 is selected from hydrogen, Fluorine, chlorine, bromine, iodine, hydroxy, methyl, ethyl, propyl, isopropyl, trifluoromethyl, trifluoroethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, 2-hydroxypropyl , Methoxy, ethoxy, propoxy, isopropoxy, nitro, carboxy, cyano, amino, methylamino
- t is selected from 1, 2, and 3.
- the compounds of the present invention are compounds of general formula I, Ia, Ib or Ic or isomers, pharmaceutically acceptable salts, solvates, crystals, electron isosteres or prodrugs, among them:
- R 1 is selected from cyclopentyl, cyclohexyl, 4-6 membered heterocycloalkyl, C 6-10 aryl, 5-10 membered heteroaryl, C 6-12 arylamino, C 5-8 heteroaryl Amino, C 6-10 aryl and 5-10 membered heterocyclic group and 5-10 membered heteroaryl and 5-6 membered heterocyclic group, which are optionally substituted by one or more C 1-3 alkyl, halogenated C 1-3 alkyl, hydroxy, hydroxy C 1-3 alkyl, halogen, oxo group, C 1-3 alkoxy, carboxy, cyano, amino, mono C 1-3 alkylamino or double C 1-3 alkylamino group;
- R 2 and R 3 are independently selected from hydrogen, fluorine, chlorine, bromine, methyl, ethyl, propyl, butyl, isopropyl, isobutyl, tert-butyl, methylamino, ethylamino, Propylamino, isopropylamino, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, thienyl, furyl, pyridyl, pyridine Azinyl, pyrimidinyl, azetidinyl, oxetanyl, tetrahydropyrrolyl, tetrahydrofuranyl, piperidinyl, tetrahydropyranyl, and morpholinyl, which are optionally substituted by one or more hydroxyl groups, Methyl
- R 4 is selected from hydrogen, hydrogen, fluorine, chlorine, bromine, hydroxy, methyl, ethyl, propyl, isopropyl, trifluoromethyl, trifluoroethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl , 2-hydroxypropyl, methoxy, ethoxy, propoxy, isopropoxy, nitro, carboxy, cyano, amino, methylamino, ethylamino, propylamino, isopropylamino, Dimethylamino, diethylamino, methylethylamino, dipropylamino, methylpropylamino, ethylpropylamino, methylacylamino, ethylacylamino, vinylacylamino, methylacyl, ethyl Acyl, vinyl acyl, aminoacyl, methylaminoacyl, ethylaminoacyl, cyclopropyl
- R 5 and R 6 are independently selected from hydrogen, fluorine, chlorine, bromine, hydroxy, methyl, ethyl, propyl, isopropyl, trifluoromethyl, trifluoroethyl, hydroxymethyl, hydroxyethyl , Hydroxypropyl, 2-hydroxypropyl, methoxy, ethoxy, propoxy, isopropoxy, nitro, carboxy, cyano, amino, methylamino, ethylamino, propylamino, iso Propylamino, dimethylamino, diethylamino, methylethylamino, dipropylamino, methylpropylamino, ethylpropylamino, methylacylamino, ethylacylamino, vinylacylamino, methyl Acyl, ethylacyl, vinylacyl, aminoacyl, methylaminoacyl, ethylaminoacyl, cyclopropy
- R 8 , R 9 and R 10 are independently selected from hydrogen, fluorine, chlorine, bromine, iodine, hydroxy, methyl, ethyl, propyl, isopropyl, trifluoromethyl, trifluoroethyl and hydroxymethyl Group, hydroxyethyl, hydroxypropyl, 2-hydroxypropyl, methoxy, ethoxy, propoxy, isopropoxy, nitro, carboxyl, cyano, amino, methylamino, ethylamino, Propylamino, isopropylamino, dimethylamino, diethylamino, methylethylamino, dipropylamino, methylpropylamino, ethylpropylamino, methylacylamino, ethylacylamino, ethylene Acylamino, methylacyl, ethylacyl, vinylacyl, aminoacyl, methylaminoacyl, eth
- X 1 is N
- X 2 is N and X 2 ′ is C (R 7 ), or X 2 is C (R 7 ) and X 2 ′ is N, where R 7 is selected from hydrogen, halogen, hydroxyl, oxo group, alkylsulfonate Acyl, alkylsulfonylalkyl, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, hydroxyalkoxy, nitro, carboxy, cyano, amino, monoalkylamino, alkylacyl Amino, alkylacyl, aminoacyl, alkylaminoacyl, dialkylamino and cycloalkyl;
- X 3 and X 4 are independently selected from N, C, CH, CH 2 , O and S;
- Y 1 and Y 2 are independently selected from NH and non-existence
- n, p, and q are independently selected from 1 and 2, respectively.
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and n are as defined in the general formula I.
- the compounds of the present invention are compounds of general formula I or Id or isomers, pharmaceutically acceptable salts, solvates, crystals, electron isosteres or prodrugs, wherein R 1 is selected From C 1-6 alkoxy, morpholinyl, piperidinyl, pyrazolyl, phenyl, pyridyl, pyridylamino, pyrrolopyrazolyl, triazolopyrazinyl, thiomorpholinyl, which Optionally substituted by one or more halogen, hydroxy, amino, carboxy, cyano, nitro, oxo, C 1-6 alkylsulfonyl, aminosulfonyl, C 1-6 alkylsulfonyl C 1- 6 alkyl, C 1-6 alkyl, C 3-10 cycloalkyl, C 3-10 heterocyclyl, C 1-6 alkyl C 3-10 heterocyclyl, C 1-6 alkoxy, halo Substitute
- R 2 and R 3 are independently selected from hydrogen, fluorine, chlorine, bromine, iodine, hydroxyl, methyl, ethyl, propyl, butyl, isopropyl, isobutyl, tert-butyl, methylamino, Ethylamino, propylamino, isopropylamino, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, thienyl, furyl, Pyridyl, pyrazinyl, pyrimidinyl, azetidinyl, oxetanyl, tetrahydropyrrolyl, tetrahydrofuranyl, piperidinyl, tetrahydropyranyl, and morpholinyl, which are optionally Multiple hydroxyl, methyl,
- R 4 is selected from the group consisting of hydrogen, aminoacyl and pyrazolylamino, the aminoacyl and pyrazolylamino optionally being substituted by one or more C 1-6 alkyl, C 1-6 alkoxy, C 6-12 aryloxy , C 1-6 alkylamino, C 3-6 cycloalkyl, C 3-6 heterocycloalkyl, C 6-12 aryl, C 5-8 heteroaryl, C 6-12 arylamino, halogen, Hydroxy, amino, nitro, carboxy, cyano, alkyl acyl, amino acyl, alkylamino acyl, sulfonyl or mercapto substitution.
- the compounds of the present invention are compounds of general formula I or Id or isomers, pharmaceutically acceptable salts, solvates, crystals, electron isosteres or prodrugs thereof, wherein X 1 is N, R 1 is selected from the following groups: R 2 is tetrahydropyranyl; R 3 is selected from C 1-6 alkyl and C 3-6 cycloalkyl; R 4 is selected from H,
- the present invention provides the following specific compounds or pharmaceutically acceptable salts, isomers, solvates, crystals or prodrugs thereof:
- the present invention provides a method for preparing a compound of the present invention or a pharmaceutically acceptable salt, isomer, solvate, crystal, or prodrug thereof, including:
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 8 , R 9 , R 10 , X 1 , X 2 , X 2 ' , X 3 , X 4 , Y 1 , Y 2 , m, n, p, q and t have the meaning in the general formula I;
- A is halogen, preferably bromine.
- the pharmaceutical composition provided by the present invention comprises the compound of the present invention or its isomer, pharmaceutically acceptable salt, solvate, crystal, electron isostere or prodrug.
- the pharmaceutical composition provided by the present invention comprises a compound of the present invention or an isomer thereof, a pharmaceutically acceptable salt, a solvate, a crystal, an isostere or prodrug of an electron, and further comprises One or more agents in the group consisting of: TGF- ⁇ R1 inhibitor, tyrosine protease inhibitor, EGFR inhibitor, VEGFR inhibitor, Bcr-Abl inhibitor, c-kit inhibitor, c-Met inhibitor Agent, Raf inhibitor, MEK inhibitor, histone deacetylase inhibitor, IDH inhibitor, VEGF antibody, EGF antibody, HIV protein kinase inhibitor, HMG-CoA reductase inhibitor, etc.
- TGF- ⁇ R1 inhibitor tyrosine protease inhibitor
- EGFR inhibitor tyrosine protease inhibitor
- VEGFR inhibitor VEGFR inhibitor
- Bcr-Abl inhibitor c-kit inhibitor
- c-Met inhibitor Agent Raf inhibitor
- MEK inhibitor histone deacetylase inhibitor
- the present invention provides compounds of the present invention or isomers, pharmaceutically acceptable salts, solvates, crystals, isosteres or prodrugs thereof, and compounds containing the present invention or isomers thereof, Pharmaceutical compositions of pharmaceutically acceptable salts, solvates, crystals, isosteres or prodrugs, and the use of the compounds or pharmaceutical compositions for the treatment and / or prevention of TGF- ⁇ R1-related diseases.
- the compound of the present invention or its isomer, pharmaceutically acceptable salt, solvate, crystal, electron isostere or prodrug can be mixed with a pharmaceutically acceptable carrier, diluent or excipient to prepare a pharmaceutical preparation , Suitable for oral or parenteral administration.
- Methods of administration include, but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, and oral routes.
- the formulation can be administered by any route, for example, by infusion or bolus injection, by the route of absorption through the epithelium or skin mucosa (e.g., oral mucosa or rectum, etc.). Administration can be systemic or local.
- formulations for oral administration include solid or liquid dosage forms, and specifically include tablets, pills, granules, powders, capsules, syrups, emulsions, suspensions, and the like.
- the formulations can be prepared by methods known in the art, and include carriers, diluents or excipients conventionally used in the field of pharmaceutical formulations.
- the present invention provides compounds or their isomers, pharmaceutically acceptable salts, solvates, crystals, electrons, etc. or prodrugs represented by the general formula I, Ia, Ib, Ic or Id of the present invention Or use of a pharmaceutical composition containing the same in the preparation of a medicament for the treatment and / or prevention of cancer, tissue hyperplasia, fibrosis or inflammatory diseases, wherein the cancer, tissue hyperplasia, fibrosis or inflammatory diseases
- the pathology includes but is not limited to: melanoma, papillary thyroid tumor, cholangiocarcinoma, colon cancer, ovarian cancer, lung cancer, malignant lymphoma, cancer and sarcoma of liver, kidney, bladder, prostate, breast and pancreas, as well as skin, colon , Primary and recurrent solid tumors or leukemia of thyroid, lung and ovary, glioblastoma (glioma), myelodysplastic syndrome (MDS), myeloprolif
- the "hydrogen”, "carbon” and “oxygen” in the compounds of the present invention include all isotopes thereof.
- Isotopes are understood to include those atoms having the same atomic number but different mass numbers.
- hydrogen isotopes include tritium and deuterium
- carbon isotopes include 13 C and 14 C
- oxygen isotopes include 16 O and 18 O.
- halogen in the present invention refers to fluorine, chlorine, bromine, and iodine.
- halogenated in the present invention means substituted with fluorine, chlorine, bromine or iodine.
- alkyl in the present invention refers to a linear or branched saturated aliphatic hydrocarbon group, preferably a linear or branched group containing 1 to 6 carbon atoms, more preferably a linear or branched group containing 1 to 3 carbon atoms
- chain groups include methyl, ethyl, n-propyl, isopropyl and the like.
- the alkyl group may be substituted or unsubstituted, and when substituted, the substituent may be at any available point of attachment.
- haloalkyl group refers to an alkyl group substituted with at least one halogen.
- hydroxyalkyl group refers to an alkyl group substituted with at least one hydroxy group.
- alkoxy in the present invention refers to -O-alkyl.
- alkoxy groups include: methoxy, ethoxy, propoxy, n-propoxy, isopropoxy, and the like.
- the alkoxy group may be optionally substituted or unsubstituted, and when substituted, the substituent may be at any available point of attachment.
- cycloalkyl in the present invention refers to a cyclic saturated hydrocarbon group such as cyclopropyl and cyclobutyl.
- heterocyclic group refers to a 3- to 12-membered non-aromatic ring system having 1 to 4 ring heteroatoms (where each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon) Group ("3-12 membered heterocyclic group").
- a heterocyclyl group containing one or more nitrogen atoms the point of attachment can be a carbon or nitrogen atom, as long as valency permits.
- Heterocyclyl groups can either be monocyclic (“monocyclic heterocyclyl") or fused, bridged or spiro ring systems (eg bicyclic systems ("bicyclic heterocyclyl”)) And may be saturated or may be partially unsaturated.
- Suitable saturated and partially saturated heterocyclic groups include, but are not limited to, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, isoxazolinyl and the like.
- Heterocyclyl bicyclic ring systems can include one or more heteroatoms in one or two rings.
- Heterocyclyl also includes ring systems where the heterocycle, as defined above, is fused with one or more carbocyclyl groups (where the point of attachment is on the carbocyclyl group or on the heterocycle), or the ring system
- the heterocycle in, as defined above, is fused with one or more aryl or heteroaryl groups (where the point of attachment is on the heterocycle), and in such cases, the number of ring members continues to be referred to as heterocycle The number of ring members in the ring system.
- each instance of heterocyclyl is independently optionally substituted, ie, unsubstituted ("unsubstituted heterocyclyl") or substituted with one or more substituents ("substituted hetero Cyclic group "), such as substituted or unsubstituted piperidinyl, substituted or unsubstituted bridged ring morpholinyl and the like.
- the heterocyclyl group is a substituted 4-10 membered heterocyclyl.
- Exemplary 5-membered heterocyclic groups fused to the C 6 aryl ring include, but are not limited to, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothiophene, benzo Oxazolone group and so on.
- Exemplary 6-membered heterocyclic groups fused to the C 6 aryl ring include, but are not limited to, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like.
- Exemplary 5- and 6-membered heterocycloalkyl groups fused to 5-membered heteroaromatic rings include, but are not limited to Wait.
- aryl group refers to an aromatic system that may contain a single ring or a fused polycyclic ring, preferably an aromatic system containing a single ring or a fused bicyclic ring, which contains 6 to 18 carbon atoms, and preferably contains about 6 to about 12 carbon atoms.
- Suitable aryl groups include but are not limited to phenyl, naphthyl, anthracenyl, tetrahydronaphthyl, fluorenyl, indanyl.
- the aryl group can be optionally substituted or unsubstituted, and when substituted, the substituent can be at any available point of attachment.
- heteroaryl in itself or in any combination of groups, such as “heteroarylamino" refers to an aryl group having at least one carbon atom replaced by a heteroatom, consisting of 5-20 atoms ( 5-20 membered heteroaryl), further preferably composed of 5-12 atoms (5-12 membered heteroaryl), the heteroatom may be O, S, N, including but not limited to imidazolyl, benzo Imidazolyl, imidazopyridyl, quinazolinone, pyrrolyl, imidazolone, furanyl, thienyl, pyrazolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, oxadiazole Group, triazolyl group, pyrimidinyl group, pyridyl group, pyrazinyl group, pyridazinyl group, pyrimidopyrazolyl group, pyrimi
- the "isomers" of the present invention are compounds that have the same molecular formula but differ in nature or in the bond sequence of their atoms or in the spatial arrangement of their atoms.
- Stereoisomers are isomers whose atoms are arranged differently in space.
- Stereoisomers that are not mirror images of each other are diastereomers and stereoisomers that are non-overlapping mirror images of each other are enantiomers.
- a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible.
- the enantiomer is characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog or by the method of rotating the plane of polarized light by the molecule and designated as right-handed or left-handed ( That is, as (+) or (-)-isomers, respectively).
- Chiral compounds can exist as a single enantiomer or a mixture thereof. A mixture containing equal proportions of enantiomers is called a "racemic mixture".
- the “pharmaceutically acceptable salts” of the present invention refer to salts of the compounds of the present invention. Such salts are safe and effective when used in mammals, and have proper biological activity.
- the "solvate” of the present invention refers to a complex formed by a combination of a solute (such as an active compound, a salt of an active compound) and a solvent (such as water) in a conventional sense.
- a solute such as an active compound, a salt of an active compound
- a solvent such as water
- the solvent refers to a solvent known or easily determined by those skilled in the art. If it is water, the solvate is often referred to as a hydrate, for example, hemihydrate, monohydrate, dihydrate, trihydrate, or their replacement amounts.
- bioelectronic isostere (or "electronic isostere” for short) of the present invention is used to define where one or more atoms (or groups of atoms) have been replaced by those atoms which have similar spatial and / or electronic characteristics
- electrospray or "electronic isostere” for short
- Crystall in the present invention refers to a solid whose internal structure is formed by repeatedly forming atoms (or groups thereof) in three dimensions, which is different from an amorphous solid that does not have such a regular internal structure.
- Prodrug refers to a compound that is converted into Formula I, Ia, Ib, Ic, or Id by reaction with an enzyme, stomach acid, etc. under physiological conditions in an organism.
- composition refers to containing any one of the compounds described herein, including the corresponding isomers, prodrugs, solvates, pharmaceutically acceptable salts or chemically protected forms thereof, and one or A mixture of multiple pharmaceutically acceptable carriers.
- excipient refers to an inert substance added to a pharmaceutical composition to further facilitate administration of the compound.
- Excipients may include calcium carbonate, calcium phosphate, various sugars and various types of starch, cellulose derivatives, gelatin, vegetable oil, polyethylene glycol.
- the "pharmaceutically acceptable carrier” of the present invention refers to a carrier that does not cause significant irritation to the organism and does not interfere with the biological activity and properties of the administered compound, and includes all solvents, diluents or other excipients, dispersants, Surfactant isotonicity agent, thickener or emulsifier, preservative, solid binder, lubricant, etc. Unless any conventional carrier medium is incompatible with the compounds of the present invention.
- Some examples of pharmaceutically acceptable carriers include, but are not limited to sugars, such as lactose; starches, such as corn starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose; malt, gelatin, and the like.
- the DMSO referred to in " 1 H NMR (400 MHz, DMSO)" of the present invention refers to hexadeuterated dimethyl sulfoxide, namely DMSO-d 6 .
- Step 1 Synthesis of 2-((7-bromoquinolin-4-yl) oxy) -1- (tetrahydro-2H-pyran-4-yl) ethan-1-one
- Step 2 (E) -2-((7-Bromoquinolin-4-yl) oxy) -3- (dimethylamino) -1- (tetrahydro-2H-pyran-4-yl) propane Synthesis of -2-en-1-one
- Step 3 Synthesis of 7-bromo-4-((3- (tetrahydro-2H-pyran-4-yl) -1H-pyrazol-4-yl) oxy) quinoline
- Step 4 Synthesis of 7-bromo-4-((1-cyclopropyl-3- (tetrahydro-2H-pyran-4-yl) -1H-pyrazol-4-yl) oxy) quinoline
- the reaction system was stirred at 75 ° C for 2 hours under an oxygen atmosphere, and cooled to room temperature.
- the reaction solution was diluted with ethyl acetate (20 mL), filtered through a short column of silica gel, and rinsed with ethyl acetate (50 mL).
- the filtrate was washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain 88 mg of the title compound.
- Step 5 2- (4-((4-((1-Cyclopropyl-3- (tetrahydro-2H-pyran-4-yl) -1H-pyrazol-4-yl) oxy) quinoline Synthesis of -7-yl) amino) pyridin-2-yl) propan-2-ol
- the preparation method is the same as that in Example 1, except that morpholine is used instead of 2- (4-amino-2-pyridyl) propane-2-ol hydrochloride to prepare the title compound.
- the preparation method is the same as that in Example 1, except that thiomorpholine-1,1-dioxide is used instead of 2- (4-amino-2-pyridyl) propane-2-ol hydrochloride to obtain the title compound .
- the preparation method is the same as that in Example 1, except that 4-methyl-4-hydroxypiperidine is used instead of 2- (4-amino-2-pyridyl) propane-2-ol hydrochloride to prepare the title compound.
- the preparation method is the same as Example 3, except that 2- (2,2,2-trifluoroethyl) -2,4,5,6-tetrahydropyrrolo [3,4-c] pyrazole hydrochloride is used The salt replaced 3- (trifluoromethyl) -5,6,7,8-tetrahydro- [1,2,4] triazolo [4,3-a] pyrazine hydrochloride to prepare the title compound.
- the preparation method is the same as that in Example 7, except that 4- (4,4,5,5-tetramethyl-1,3,2-dioxoborane-2-yl) -1H-pyrazole is used instead of 1- Methyl-1H-pyrazole-4-boronic acid pinacol to prepare the title compound.
- Example 11 1- (4- (4-((1-cyclopropyl-3- (tetrahydro-2H-pyran-4-yl) -1H-pyrazol-4-yl) oxy) quinoline- 7-yl) -1H-pyrazol-1-yl) -2-methylpropan-2-ol
- the preparation method is the same as that of Example 7, except that the commercially available raw material 1-isopropyl-1H-pyrazole-4-boronic acid pinacol ester is used instead of 1-methyl-1H-pyrazole-4-boronic acid pin That alcohol ester, the title compound.
- Step 1 2 – ((7-Bromoquinolin-4-yl) oxy) -1-phenylethyl-1-one
- Step 2 Preparation of 2-((7-bromoquinolin-4-yl) oxy) -3- (dimethylamino) -1-phenylprop-2-en-1-one
- Step 2 Preparation of 7-bromo-4-((3-phenyl-1H-pyrazol-4-yl) oxy) quinoline
- Step 3 Preparation of 7-bromo-4-((1-cyclopropyl-3-phenyl-1H-pyrazol-4-yl) oxy) quinoline
- the reaction mixture was stirred and reacted under an oxygen atmosphere at 75 ° C for 2h, and cooled to room temperature. Dilute with ethyl acetate (100 mL), filter through a short column of silica gel, and rinse with ethyl acetate. The filtrate was washed with water and a saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, the filtrate was concentrated, and silica gel column chromatography was performed to obtain the title compound. LC-MS m / z: 405.9, 407.9 [M + H] + .
- Step 4 4-((1-Cyclopropyl-3-phenyl-1H-pyrazol-4-yl) oxy) -7- (1-methyl-1H-pyrazol-4-yl) quinoline Preparation
- Step 1 4-((1-Cyclopropyl-3- (tetrahydro-2H-pyran-4-yl) -1H-pyrazol-4-yl) oxy) -7- (4,4,5 Of 5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) quinoline
- Step 2 2- (4- (4-((1-Cyclopropyl-3- (tetrahydro-2H-pyran-4-yl) -1H-pyrazol-4-yl) oxy) quinoline- Synthesis of 7-yl) pyridin-2-yl) propan-2-ol
- Step 3 Preparation of 1- (dimethylamino) -3-oxo-3- (tetrahydro-2H-pyran-4-yl) prop-1-en-2-ylbenzoate
- Step 4 Preparation of methyl 3- (tetrahydro-2H-pyran-4-yl) -1H-pyrazol-4-ylbenzoate
- Step 7 4-((1-cyclopropyl-3- (tetrahydro-2H-pyran-4-yl) -1H-pyrazol-4-yl) oxy) -7-methoxyquinoline- Preparation of 6-formamide
- Step 2 4-((1-Cyclopropyl-3- (tetrahydro-2H-pyran-4-yl) -1H-pyrazol-4-yl) oxy) -7-methoxy-N- (1-methyl-1H-pyrazol-4-yl) quinoline-6-amine
- Step 3 4-((1-Cyclopropyl-3- (tetrahydro-2H-pyran-4-yl) -1H-pyrazol-4-yl) oxa) -7-methoxy-N- ( Synthesis of 1- (oxetane-3-yl) -1H-pyrazol-4-yl) quinoline-6-amine
- the preparation method is the same as Example 7, except that (1- (methylsulfonyl) -1,2,3,6-tetrahydropyridin-4-yl) boronic acid is used instead of 1-methyl-1H-pyrazole- 4-Poronic acid borate to prepare the title compound.
- the preparation method is the same as Example 1, except that 2- (trifluoromethyl) -5,6,7,8-tetrahydro- [1,2,4] triazolo [1,5-a] pyridine is used Substitute azine for 2- (4-amino-2-pyridyl) propane-2-ol hydrochloride to prepare the title compound.
- the compound of the present invention prepared in the above examples after each compound was formulated into 10 mM with DMSO, was sequentially diluted to 3.333 ⁇ M, 1.111 ⁇ M, 370 nM, 123 nM, 41 nM, 14 nM, 4.6 nM, 1.5 nM, 0.5 nM.
- ALK5 purchased from Carna, Cat. No. 09-141; p38 ⁇ was purchased from Carna, Cat. No. 04-152; TGF ⁇ R1 peptide was purchased from SignalChem, Cat. No. T36-58; Sulfoxide (DMSO), purchased from Sigma, USA; EDTA, purchased from Sigma, USA; ADP-Glo Kinase Assay, purchased from Promega, Cat. No. v9102 / 3, 1 ⁇ kinase buffer (40mM Tris, pH 7.5, 0.10% BSA, 20 mM MgCl 2 , 1 mM DTT), prepared immediately before use.
- the final concentration of the compound is 10 ⁇ M, which is configured to be 50-fold concentration, ie 500 ⁇ M: add 95 ⁇ l of 100% DMSO to the second well of the 96-well plate, and then add 5 ⁇ l of 10 mM compound solution. Formulated into a 1000 ⁇ M compound solution. Add 60 ⁇ l of 100% DMSO to the other wells. Take 30 ⁇ l of compound from the second well and add it to the third well, and make a 3-fold dilution in turn, diluting a total of 10 concentrations.
- Dilution instrument automatic micropore pipette (Precision PRC384U).
- FAM-labeled polypeptide and ATP were added to 1-fold kinase buffer to form a 2-fold substrate solution.
- the 384-well plate was incubated at 28 degrees for 120 minutes.
- Percent inhibition (max-sample RLU) / (max-min) * 100. "Min” is the fluorescence reading of the control sample without enzyme; “max” is the fluorescence reading of the sample added DMSO as a control.
- the compounds of the present invention have a good inhibitory activity against ALK5 kinase, while having a low inhibitory effect on p38 ⁇ and high selectivity. It shows that the compound of the present invention has higher side effects and lower side effects.
- Test compound The compound of the present invention prepared in the above examples, each compound was formulated into 4mM with DMSO, and then sequentially diluted 4 times to 20000.00nM, 5000.00nM, 1250.00nM, 312.5nM, 78.125nM, 19.53nM, 4.88nM, 1.22nM.
- Luc-Smad2 / 3-NIH3T3 mouse fibroblasts (over-expressed SMAD2 after engineering, 3-responsive promoter) were donated by the Laboratory of China Pharmaceutical University.
- DMEM purchased from Invitrogen, USA
- FBS purchased from Invitrogen, USA
- DMSO purchased from Sigma, USA
- GloLysis Buffer, purchased from Progema, USA
- Bright-Glo Luciferaseassay system purchased from American Promega
- TGF ⁇ purchased from American PeproTech.
- Cell resuscitation Dissolve the cells in a 37-degree water bath, then transfer to 15mL of pre-warmed medium, centrifuge at 1000rpm for 5 minutes, discard the medium, resuspend the cells with 15mL of fresh medium, and transfer to a 10cm Petri dish And placed in a 37 ° C, 5% CO 2 incubator, and the cells were replaced with fresh medium after 24 hours.
- Cell passaging Transfer the recovered cells to a 50 mL sterile centrifuge tube, centrifuge at 1000 rpm for 5 minutes, discard the culture medium, take a uniformly dispersed cell count, adjust the appropriate cell concentration to 15 mL of fresh culture medium, and add it to a 10 cm Petri dish Incubate in a 37 ° C, 5% CO 2 incubator.
- Luc-Smad2 / 3-NIH3T3 cells were normally cultured in a 10cm Petri dish until the confluence reached 80% -90%. After digestion, they were collected in 15mL centrifuge tubes. After centrifugation at 1000xg for 5 minutes, the supernatant was removed and resuspended in 1mL medium Afterwards, dilute the count by 10 times, dilute the cells according to the result of the count, and transfer the cell number of 4 ⁇ 10 3 / well into a 96-well plate (add 100 ⁇ l of resuspended cells per well).
- the drug is weighed 1-2 mg (pre-weighed) and formulated into 4 mM stock solution using DMSO. After 24 hours, the medium was removed. Dilute the drug with 2% FBS medium and add 100 ⁇ l 1x drug solution to make the final drug concentration 20002000nM, 5000.00nM, 1250.00nM, 312.5nM, 78.125nM, 19.53nM, 4.88nM, 1.22nM, TGF ⁇ 1 final concentration 4 ng / mL, diluted with 2% FBS medium together with the compound.
- the compounds of the present invention show good inhibitory activity on the TGF ⁇ -ALK5-SMAD2 / 3 signaling pathway in NIH3T3 cells, and are very promising as therapeutic agents for various cancer-related diseases.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (10)
- 一种通式I的化合物或其药学上可接受的盐、异构体、溶剂化物、结晶或前药,其中,X 1选自N和CH;R 1选自羟基、氰基、羧基、硝基、烷基、卤代烷基、羟基烷基、烷氧基、环烷基氧基、杂环烷基氧基、环烷基烷氧基、杂环基烷氧基、环烷基烷基、杂环基烷基、单烷基氨基、双烷基氨基、环烷基氨基、杂环基氨基、芳基氨基、杂芳基氨基、环烷基、杂环基、芳基、杂芳基、芳基并杂环基和杂芳基并杂环基,其任选被一个或多个卤素、羟基、氨基、羧基、氰基、硝基、氧代基团、烷基磺酰基、氨基磺酰基、烷基磺酰基烷基、烷基、环烷基、杂环基、烷基杂环基、烷氧基、卤代烷基、羟基烷基、氨基烷基、羧基烷基、氰基烷基、硝基烷基、环烷基烷基、杂环烷基烷基、烷氧基烷基、单烷基氨基、双烷基氨基、烷基酰基、烷氧基酰基、烷基酰基氧基、氨基酰基、烯基酰基、单烷基氨基烯基酰基、双烷基氨基烯基酰基、单烷基氨基酰基、双烷基氨基酰基、烷基酰基氨基或烷基酰基氨基烷基取代;R 2、R 3分别独立地选自氢、卤素、羟基、烷基、卤代烷基、羟基烷基、烷氧基、卤代烷氧基、羟基烷氧基、硝基、羧基、氰基、氨基、单烷基氨基、烷基酰基氨基、烷基酰基、氨基酰基、烷基氨基酰基、双烷基氨基、烯基、炔基、环烷基、杂环基、芳基和杂芳基,其中所述卤素、羟基、烷基、卤代烷基、羟基烷基、烷氧基、卤代烷氧基、羟基烷氧基、硝基、羧基、氰基、氨基、单烷基氨基、烷基酰基氨基、烷基酰基、氨基酰基、烷基氨基酰基、双烷基氨基、烯基、炔基、环烷基、杂环基、芳基或杂芳基任选被一个或者多个烷基、卤代烷基、羟基、羟基烷基、卤素、氧代基团、烷氧基、羧基、氰基、氨基、单烷基氨基或双烷基氨基取代;R 4选自氢、卤素、羟基、烷基、卤代烷基、羟基烷基、烷氧基、卤代烷氧基、羟基烷氧基、硝基、羧基、氰基、氨基、烷基氨基、烷基酰基氨基、烷基酰基、氨基酰基、烷基氨基酰基、环烷基、杂环烷基、芳基、杂芳基、环烷基氨基、杂环烷基芳基、芳基氨基和杂芳基氨基,其中所述卤素、羟基、烷基、卤代烷基、羟基烷基、烷氧基、卤代烷氧基、羟基烷氧基、硝基、羧基、氰基、氨基、烷基氨基、烷基酰基氨基、烷基酰基、氨基酰基、烷基氨基酰基、环烷基、杂环烷基、芳基、杂芳基、环烷基氨基、杂环烷基芳基、芳基氨基和杂芳基氨基任选被一个或多个烷基、烷氧基、芳氧基、烷氨基、环烷基、杂环烷基、芳基、杂芳基、芳基氨基、卤素、羟基、氨基、硝基、羧基、氰基、烷基酰基、氨基酰基、烷氨基 酰基、磺酰基或巯基取代;R 5、R 6分别独立地选自氢、卤素、羟基、烷基、卤代烷基、羟基烷基、烷氧基、卤代烷氧基、羟基烷氧基、硝基、羧基、氰基、氨基、单烷基氨基、烷基酰基氨基、烷基酰基、氨基酰基、烷基氨基酰基、双烷基氨基、环烷基;和m、n分别独立地选自1、2和3。
- 根据权利要求1所述的化合物或其异构体、药学上可接受的盐、结晶、溶剂化物或前药,其中R 1选自羟基、氰基、羧基、硝基、C 1-6烷基、卤代C 1-6烷基、羟基C 1-6烷基、C 1-6烷氧基、C 3-6环烷基氧基、C 3-6杂环烷基氧基、C 3-6环烷基C 1-3烷氧基、C 3-6杂环基C 1-3烷氧基、C 3-6环烷基C 1-3烷基、C 3-6杂环基C 1-3烷基、单C 1-6烷基氨基、双C 1-6烷基氨基、C 3-6环烷基氨基、C 3-6杂环基氨基、C 6-12芳基氨基、C 5-8杂芳基氨基、C 3-6环烷基、C 3-6杂环基、C 6-12芳基、C 5-12杂芳基、C 6-12芳基并C 3-10杂环基和C 5-12杂芳基并C 3-6杂环基,其任选被一个或多个卤素、羟基、氨基、羧基、氰基、硝基、氧代基团、C 1-6烷基磺酰基、氨基磺酰基、C 1-6烷基磺酰基C 1-6烷基、C 1-6烷基、C 3-10环烷基、C 3-10杂环基、C 1-6烷基C 3-10杂环基、C 1-6烷氧基、卤代C 1-6烷基、羟基C 1-6烷基、氨基C 1-6烷基、羧基C 1-6烷基、氰基C 1-6烷基、硝基C 1-6烷基、C 3-6环烷基C 1-6烷基、C 3-6杂环烷基C 1-6烷基、C 1-6烷氧基C 1-6烷基、单C 1-6烷基氨基、双C 1-6烷基氨基、C 1-6烷基酰基、C 1-6烷氧基酰基、C 1-6烷基酰基氧基、氨基酰基、C 2-10烯基酰基、单C 1-6烷基氨基C 2-10烯基酰基、双C 1-6烷基氨基C 2-10烯基酰基、单C 1-6烷基氨基酰基、双C 1-6烷基氨基酰基、C 1-6烷基酰基氨基或C 1-6烷基酰基氨基C 1-6烷基取代。
- 根据权利要求1或2所述的化合物或其异构体、药学上可接受的盐、结晶、溶剂化物或前药,其中,R 2、R 3分别独立地选自氢、氟、氯、溴、碘、羟基、C 1-6烷基、卤代C 1-6烷基、羟基C 1-6烷基、C 1-6烷氧基、卤代C 1-6烷氧基、羟基C 1-6烷氧基、硝基、羧基、氰基、氨基、单C 1-6烷基氨基、C 1-6烷基酰基氨基、C 1-6烷基酰基、氨基酰基、C 1-6烷基氨基酰基、双C 1-6烷基氨基、C 2-10烯基、C 2-10炔基、C 3-10环烷基、3-10元杂环烷基、C 6-18芳基和5-18元杂芳基,其中所述所述氟、氯、溴、碘、羟基、C 1-6烷基、卤代C 1-6烷基、羟基C 1-6烷基、C 1-6烷氧基、卤代C 1-6烷氧基、羟基C 1-6烷氧基、硝基、羧基、氰基、氨基、单C 1-6烷基氨基、C 1-6烷基酰基氨基、C 1-6烷基酰基、氨基酰基、C 1-6烷基氨基酰基、双C 1-6烷基氨基、C 2-10烯基、C 2-10炔基、C 3-10环烷基、3-10元杂环烷基、C 6-18芳基和5-18元杂芳基任选被一个或者多个烷基、卤代烷基、羟基、羟基烷基、卤素、氧代基团、烷氧基、羧基、氰基、氨基、单烷基氨基或双烷基氨基取代。
- 根据权利要求1~3之任一项所述的化合物或其异构体、药学上可接受的盐、结晶、溶剂化物或前药,R 4选自氢、卤素、羟基、C 1-6烷基、卤代C 1-6烷基、羟基C 1-6烷基、C 1-6烷氧基、卤代C 1-6烷氧基、羟基C 1-6烷氧基、硝基、羧基、 氰基、氨基、C 1-6烷基氨基、C 1-6烷基酰基氨基、C 1-6烷基酰基、氨基酰基、C 1-6烷基氨基酰基、C 3-8环烷基、C 3-8杂环烷基、C 6-12芳基、C 5-12杂芳基、C 3-8环烷基氨基、C 3-8杂环烷基芳基、C 6-12芳基氨基和C 5-8杂芳基氨基,其中所述卤素、羟基、C 1-6烷基、卤代C 1-6烷基、羟基C 1-6烷基、C 1-6烷氧基、卤代C 1-6烷氧基、羟基C 1-6烷氧基、硝基、羧基、氰基、氨基、C 1-6烷基氨基、C 1-6烷基酰基氨基、C 1-6烷基酰基、氨基酰基、C 1-6烷基氨基酰基、C 3-8环烷基、C 3-8杂环烷基、C 6-12芳基、C 5-12杂芳基、C 3-8环烷基氨基、C 3-8杂环烷基芳基、C 6-12芳基氨基和C 5-8杂芳基氨基任选被一个或多个C 1-6烷基、C 1-6烷氧基、C 6-12芳氧基、C 1-6烷氨基、C 3-6环烷基、C 3-6杂环烷基、C 6-12芳基、C 5-8杂芳基、C 6-12芳基氨基、卤素、羟基、氨基、硝基、羧基、氰基、烷基酰基、氨基酰基、烷氨基酰基、磺酰基或巯基取代;R 5、R 6分别独立地选自氢、卤素、羟基、C 1-6烷基、卤代C 1-6烷基、羟基C 1-6烷基、C 1-6烷氧基、卤代C 1-6烷氧基、羟基C 1-6烷氧基、硝基、羧基、氰基、氨基、单C 1-6烷基氨基、C 1-6烷基酰基氨基、C 1-6烷基酰基、氨基酰基、C 1-6烷基氨基酰基、双C 1-6烷基氨基和C 3-10环烷基。
- 根据权利要求1~4之任一项所述的化合物或其异构体、药学上可接受的盐、溶剂化物、结晶或前药,其中R 1选自C 1-6烷氧基、吗啉基、哌啶基、吡唑基、苯基、吡啶基、吡啶氨基、吡咯并吡唑基、三唑并吡嗪基、硫代吗啉基,其任选被一个或多个卤素、羟基、氨基、羧基、氰基、硝基、氧代基团、C 1-6烷基磺酰基、氨基磺酰基、C 1-6烷基磺酰基C 1-6烷基、C 1-6烷基、C 3-10环烷基、C 3-10杂环基、C 1-6烷基C 3-10杂环基、C 1-6烷氧基、卤代C 1-6烷基、羟基C 1-6烷基、氨基C 1-6烷基、羧基C 1-6烷基、氰基C 1-6烷基、硝基C 1-6烷基、C 3-6环烷基C 1-6烷基、C 3-6杂环烷基C 1-6烷基、C 1-6烷氧基C 1-6烷基、单C 1-6烷基氨基、双C 1-6烷基氨基、C 1-6烷基酰基、C 1-6烷氧基酰基、C 1-6烷基酰基氧基、氨基酰基、C 2-10烯基酰基、单C 1-6烷基氨基C 2-10烯基酰基、双C 1-6烷基氨基C 2-10烯基酰基、单C 1-6烷基氨基酰基、双C 1-6烷基氨基酰基、C 1-6烷基酰基氨基或C 1-6烷基酰基氨基C 1-6烷基取代;R 2、R 3分别独立地选自氢、氟、氯、溴、碘、羟基、甲基、乙基、丙基、丁基、异丙基、异丁基、叔丁基、甲基氨基、乙基氨基、丙基氨基、异丙基氨基、环丙基、环丁基、环戊基、环己基、苯基、吡咯基、咪唑基、吡唑基、噻唑基、噻吩基、呋喃基、吡啶基、吡嗪基、嘧啶基、氮杂环丁基、氧杂环丁基、四氢吡咯基、四氢呋喃基、哌啶基、四氢吡喃基和吗啉基,它们任选被一个或多个羟基、甲基、乙基、丙基、丁基、异丙基、异丁基、叔丁基、羧基、氟、氯、溴、三氟甲基、三氟乙基、氨基甲基、氨基乙基、氨基丙基、甲基氨基、乙基氨基、丙基氨基、异丙基氨基、甲氧基、乙氧基、丙氧基、异丙氧基、氧代基团、甲酰基、乙酰基、丙酰基、异丙酰基、乙烯基、丙烯基、乙炔基、并炔基、苯基、萘基、吡咯基、咪唑基、吡唑基、噻唑基、噻吩基、呋喃基、吡啶基、吡嗪基和嘧啶基取代;和R 4选自氢、氨酰基和吡唑氨基,所述氨酰基和吡唑氨基任选被一个或多个C 1-6烷基、C 1-6烷氧基、C 6-12芳氧基、C 1-6烷氨基、C 3-6环烷 基、C 3-6杂环烷基、C 6-12芳基、C 5-8杂芳基、C 6-12芳基氨基、卤素、羟基、氨基、硝基、羧基、氰基、烷基酰基、氨基酰基、烷氨基酰基、磺酰基或巯基取代。
- 根据权利要求1~5之任一项所述的化合物或其异构体、药学上可接受的盐、溶剂化物、结晶或前药,其中通式I具有以下通式Ia的结构,其中,R 2、R 3、R 4、R 5、R 6、m、n如权利要求1~5中所定义;X 2和X 2’分别独立地选自N和C(R 7),其中R 7选自氢、卤素、羟基、氧代基团、烷基磺酰基、烷基磺酰基烷基、烷基、卤代烷基、羟基烷基、烷氧基、卤代烷氧基、羟基烷氧基、硝基、羧基、氰基、氨基、单烷基氨基、烷基酰基氨基、烷基酰基、氨基酰基、烷基氨基酰基、双烷基氨基和环烷基;R 8选自氢、卤素、羟基、氧代基团、烷基磺酰基、烷基磺酰基烷基、烷基、卤代烷基、羟基烷基、烷氧基、卤代烷氧基、羟基烷氧基、硝基、羧基、氰基、氨基、单烷基氨基、烷基酰基氨基、烷基酰基、氨基酰基、烷基氨基酰基、双烷基氨基和环烷基;和p选自1、2和3。
- 一种药物组合物,其包含权利要求1~8之任一项所述的化合物或其药学上可接受的盐、异构体、溶剂化物、前药和药学上可接受的载体。
- 权利要求1~8之任一项所述的化合物或其药学上可接受的盐、异构体、溶剂化物或前药或权利要求9所述的药物组合物在制备用于治疗和/或预防TGF-βR1相关疾病的药物中的应用,优选地,所述疾病为癌症、组织增生类疾病、纤维化或炎性疾病的药物中的应用。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021520911A JP2022504982A (ja) | 2018-10-18 | 2019-10-17 | TGF-βR1阻害剤としての化合物及びその応用 |
US17/285,180 US20210395235A1 (en) | 2018-10-18 | 2019-10-17 | COMPOUND AS TGF-beta R1 INHIBITOR AND APPLICATION THEREOF |
EP19874641.4A EP3868755A4 (en) | 2018-10-18 | 2019-10-17 | TGF-BETA R1 INHIBITOR COMPOUND AND USE THEREOF |
CA3116425A CA3116425A1 (en) | 2018-10-18 | 2019-10-17 | Compound as tgf-.beta. r1 inhibitor and application thereof |
KR1020217014232A KR20210076069A (ko) | 2018-10-18 | 2019-10-17 | TGF-βR1 억제제로서의 화합물 및 이의 적용 |
CN201980067259.9A CN112839941B (zh) | 2018-10-18 | 2019-10-17 | 作为TGF-βR1抑制剂的化合物及其应用 |
AU2019362242A AU2019362242A1 (en) | 2018-10-18 | 2019-10-17 | Compound as TGF-β R1 inhibitor and application thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811211890 | 2018-10-18 | ||
CN201811211890.5 | 2018-10-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020078402A1 true WO2020078402A1 (zh) | 2020-04-23 |
Family
ID=70283713
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2019/111568 WO2020078402A1 (zh) | 2018-10-18 | 2019-10-17 | 作为TGF-βR1抑制剂的化合物及其应用 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20210395235A1 (zh) |
EP (1) | EP3868755A4 (zh) |
JP (1) | JP2022504982A (zh) |
KR (1) | KR20210076069A (zh) |
CN (2) | CN112839941B (zh) |
AU (1) | AU2019362242A1 (zh) |
CA (1) | CA3116425A1 (zh) |
TW (1) | TW202028195A (zh) |
WO (1) | WO2020078402A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021129621A1 (zh) * | 2019-12-23 | 2021-07-01 | 江苏先声药业有限公司 | 吡唑类化合物 |
CN114437082A (zh) * | 2020-11-06 | 2022-05-06 | 江苏先声药业有限公司 | 喹啉类化合物 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113698395B (zh) * | 2020-05-22 | 2023-12-08 | 赛诺哈勃药业(成都)有限公司 | 转化生长因子受体拮抗剂、其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1514828A (zh) * | 2001-04-10 | 2004-07-21 | 治疗hiv的吡唑衍生物 | |
WO2006040522A1 (en) * | 2004-10-12 | 2006-04-20 | Astrazeneca Ab | Quinoline derivatives |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004026302A1 (en) * | 2002-09-19 | 2004-04-01 | Eli Lilly And Company | Methods of inhibiting tgf beta with substituted pyrazoles |
EP1724268A4 (en) * | 2004-02-20 | 2010-04-21 | Kirin Pharma Kk | COMPOUND HAVING TGF-BETA INHIBITING ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME |
AP2008004463A0 (en) * | 2005-11-08 | 2008-06-30 | Pfizer Ltd | pyrazole derivatives and their medical use |
KR20130025860A (ko) * | 2009-11-07 | 2013-03-12 | 메르크 파텐트 게엠베하 | Tgf-베타 수용체 키나아제 저해제로서의 헤테로아릴아미노퀴놀린 |
JO3336B1 (ar) * | 2014-10-07 | 2019-03-13 | Lilly Co Eli | مركبات أمينو بيريديلوكسي بيرازول |
-
2019
- 2019-10-17 TW TW108137448A patent/TW202028195A/zh unknown
- 2019-10-17 KR KR1020217014232A patent/KR20210076069A/ko not_active Application Discontinuation
- 2019-10-17 EP EP19874641.4A patent/EP3868755A4/en not_active Withdrawn
- 2019-10-17 US US17/285,180 patent/US20210395235A1/en not_active Abandoned
- 2019-10-17 WO PCT/CN2019/111568 patent/WO2020078402A1/zh unknown
- 2019-10-17 CN CN201980067259.9A patent/CN112839941B/zh active Active
- 2019-10-17 AU AU2019362242A patent/AU2019362242A1/en not_active Abandoned
- 2019-10-17 CA CA3116425A patent/CA3116425A1/en not_active Abandoned
- 2019-10-17 JP JP2021520911A patent/JP2022504982A/ja active Pending
- 2019-10-18 CN CN201910991023.6A patent/CN111072645B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1514828A (zh) * | 2001-04-10 | 2004-07-21 | 治疗hiv的吡唑衍生物 | |
WO2006040522A1 (en) * | 2004-10-12 | 2006-04-20 | Astrazeneca Ab | Quinoline derivatives |
Non-Patent Citations (4)
Title |
---|
LING ET AL., CURRENT PHARMACEUTICAL BIOTECHNOLOGY, vol. 12, 2011, pages 2190 - 2202 |
PLE, P. A. ET AL.: "Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 22, 12 November 2011 (2011-11-12), XP029121570, DOI: 20200103141331X * |
See also references of EP3868755A4 |
YAMAZAKI, DIGESTIVE DISEASE, vol. 29, 2011, pages 284 - 288 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021129621A1 (zh) * | 2019-12-23 | 2021-07-01 | 江苏先声药业有限公司 | 吡唑类化合物 |
CN114728980A (zh) * | 2019-12-23 | 2022-07-08 | 江苏先声药业有限公司 | 吡唑类化合物 |
CN114437082A (zh) * | 2020-11-06 | 2022-05-06 | 江苏先声药业有限公司 | 喹啉类化合物 |
Also Published As
Publication number | Publication date |
---|---|
EP3868755A1 (en) | 2021-08-25 |
CN112839941A (zh) | 2021-05-25 |
KR20210076069A (ko) | 2021-06-23 |
TW202028195A (zh) | 2020-08-01 |
CA3116425A1 (en) | 2020-04-23 |
CN111072645B (zh) | 2022-06-07 |
US20210395235A1 (en) | 2021-12-23 |
CN111072645A (zh) | 2020-04-28 |
CN112839941B (zh) | 2022-06-07 |
EP3868755A4 (en) | 2022-05-25 |
AU2019362242A1 (en) | 2021-05-27 |
JP2022504982A (ja) | 2022-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6776446B2 (ja) | Retキナーゼ阻害剤としての置換ピラゾロ[1,5−a]ピリジン化合物 | |
KR102007056B1 (ko) | 과증식성 질환 치료시 Bub1 키나제 저해제로 사용하기 위한 치환된 벤질인다졸 | |
TWI557131B (zh) | 化學物質、其用途及包含該化學物質之產品 | |
EP4031547B1 (en) | Plasma kallikrein inhibitors and uses thereof | |
WO2020249079A1 (zh) | 一种shp2磷酸酶变构抑制剂 | |
WO2021143701A1 (zh) | 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用 | |
WO2020078402A1 (zh) | 作为TGF-βR1抑制剂的化合物及其应用 | |
WO2020020288A1 (zh) | 作为溴区结构域蛋白抑制剂的亚氨基砜类化合物、药物组合物及其医药用途 | |
WO2021164746A1 (zh) | 取代芳基类化合物 | |
CN113072551A (zh) | 含氮联苯类衍生物抑制剂、其制备方法和应用 | |
WO2021032004A9 (zh) | 氮杂芳基化合物及其应用 | |
WO2018121766A1 (zh) | 含氮稠杂环化合物、其制备方法、中间体、组合物和应用 | |
WO2023280254A1 (zh) | 一种tead抑制剂 | |
WO2023165581A1 (zh) | 一种吡啶类衍生物及其用途 | |
KR20240091009A (ko) | 신규 스피로 화합물 | |
WO2022206730A1 (zh) | 嘧啶并吡嗪酮化合物及其用途 | |
WO2022127753A1 (zh) | 稠环类AhR抑制剂 | |
CN107793397B (zh) | 取代的嘧啶类pi3k抑制剂的光学异构体及其应用 | |
TWI707853B (zh) | 1,2-二氫-1,6-萘啶類衍生物、其製備方法、其藥物組合物及其在醫藥上的用途 | |
WO2024017294A1 (zh) | 作为激酶抑制剂的喹唑啉酮衍生物的制备及其用途 | |
WO2024140933A1 (zh) | 喜树碱衍生物、药物组合物及其制备方法和应用 | |
WO2024114680A9 (zh) | 杂环化合物、药物组合物及其应用 | |
WO2023109883A1 (zh) | 一类芳杂环取代的化合物及其制备方法和用途 | |
WO2024083208A1 (zh) | Kif18a蛋白抑制剂 | |
CN113527305A (zh) | 喹啉类TGF-β1抑制剂的可药用盐及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19874641 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3116425 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021520911 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20217014232 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019874641 Country of ref document: EP Effective date: 20210518 |
|
ENP | Entry into the national phase |
Ref document number: 2019362242 Country of ref document: AU Date of ref document: 20191017 Kind code of ref document: A |